Supplementary Online Content


eFigure 1. Time to discontinuation by randomly allocated drug.

eFigure 2. Flow Chart of the Swedish pharmacotherapy (Swefot) trial and number of patients by type of analysis in the present study.

eFigure 3. Monthly days on sick leave and disability pension in randomized and non-randomized patients.

This supplementary material has been provided by the authors to give readers additional information about their work.
Drug Discontinuation

HR_{12\text{m}}=0.50; 95\% CI, 0.31 to 0.82; P=.006
HR_{21\text{m}}=0.51; 95\% CI, 0.31 to 0.82; P=.006

Number at risk (Discontinuations)

- Biologic treatment
  - 98 (2)
  - 96 (8)
  - 88 (4)
  - 84 (3)
  - 81 (3)
  - 78 (3)
  - 75 (3)
  - 72

- Conventional treatment
  - 95 (5)
  - 90 (16)
  - 74 (12)
  - 62 (3)
  - 59 (4)
  - 55 (1)
  - 54 (2)
  - 52

eFigure 1 Time to discontinuation by randomly allocated drug

HR: Hazard ratio

©2013 American Medical Association. All rights reserved.
**eFigure 2** Flow chart of the Swedish pharmacotherapy (Swefot) trial and number of patients by type of analysis in the present study

©2013 American Medical Association. All rights reserved.
**eFigure 3** Mean monthly days (maximum 30 days) on sick leave and disability pension in relation to date of randomization for randomized and non-randomized patients

Run-in: Mono-therapy with methotrexate; Bars indicate standard errors

©2013 American Medical Association. All rights reserved.